α-Arbutin

• Description :

  α-Arbutin (4-Hydroxyphenyl α-D-glucopyranoside) is a tyrosinase inhibitor, which is used as an effective skin whiteners. α-Arbutin is promising for research of various diseases such as hyperpigmentation disorders, types of cancers, central nervous system disorders, osteoporosis, diabetes[1][2][3][4].

• CAS Number :

  [84380-01-8]

• Product Name Alternative :

  4-Hydroxyphenyl α-D-glucopyranoside

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Tyrosinase

• Type :

  Natural Products

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cancer; Metabolic Disease; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/α-arbutin.html

• Concentration :

  10mM

• Purity :

  99.98

• Solubility :

  H2O : 125 mg/mL (ultrasonic)

• Smiles :

  OC(C=C1)=CC=C1O[C@H]2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)CO

• Molecular Formula :

  C12H16O7

• Molecular Weight :

  272.25

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Avonto C, et al. Comparative studies on the chemical and enzymatic stability of alpha- and beta-arbutin.Int J Cosmet Sci. 2016 Apr;38 (2) :187-93.|[2]Saeedi M, et al. A comprehensive review of the therapeutic potential of α-arbutin. Phytother Res. 2021 Aug;35 (8) :4136-4154. |[3]Sugimoto K, et al. Inhibitory effects of alpha-arbutin on melanin synthesis in cultured human melanoma cells and a three-dimensional human skin model. Biol Pharm Bull. 2004 Apr;27 (4) :510-4.|[4]Hazman Ö, et al. Two faces of arbutin in hepatocellular carcinoma (HepG2) cells: Anticarcinogenic effect in high concentration and protective effect against cisplatin toxicity through its antioxidant and anti-inflammatory activity in low concentration[J]. Biologia, 2022, 77 (1) : 225-239.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Natural Products

• Clinical Information :

  No Development Reported